Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hunan Fangsheng Pharmaceutical Co., Ltd. specializes in the development and manufacturing of generic and specialty pharmaceuticals, particularly in the areas of oncology and cardiovascular treatments. The company operates primarily in China, leveraging its strong R&D capabilities and a robust distribution network to maintain a competitive edge in a rapidly evolving market.
Hunan Fangsheng generates revenue through the sale of generic drugs and specialty pharmaceuticals, which are often sold at competitive prices due to their established market presence. The company benefits from economies of scale in production and a strong pipeline of new drug approvals, allowing for pricing power in certain therapeutic areas.
Approval of new drug applications, particularly in oncology and cardiovascular segments
Changes in government healthcare policies affecting drug pricing and reimbursement
Market share shifts due to competitive pressures from both domestic and international players
Fluctuations in raw material costs impacting gross margins
Regulatory changes in drug approval processes that could delay product launches
Technological disruption in drug development and manufacturing processes
Intensifying competition from both domestic generic manufacturers and multinational pharmaceutical companies
Potential for price erosion in key therapeutic areas due to increased competition
Moderate liquidity risk as indicated by a current ratio of 0.90
Potential future pension obligations if applicable
moderate - the pharmaceutical industry tends to be less sensitive to economic cycles, but healthcare spending can be affected by GDP growth and consumer spending patterns.
Interest rates can impact Hunan Fangsheng's cost of capital for R&D investments and operational financing, potentially affecting valuation multiples if rates rise significantly.
minimal - the company has a low debt/equity ratio (0.25), indicating limited reliance on external financing.
value - the company's strong margins and low debt levels may attract value-focused investors looking for stability in the healthcare sector.
moderate - the stock has shown volatility with a 1-year return of -13.7%, indicating some market sensitivity.